We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDPH
RNS Number : 1966Q
Dechra Pharmaceuticals PLC
04 June 2018
04 June 2018
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 71,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List.
These Shares are being reserved under a block listing and will be issued pursuant to the following scheme:
Scheme Shares
Unapproved Share Scheme 36,000
Long Term Incentive Plan (LTIP) 35,000
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on 5 June 2018.
For further information
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ALSUGUAGQUPRGUC
(END) Dow Jones Newswires
June 04, 2018 06:17 ET (10:17 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
